Format

Send to

Choose Destination
ChemMedChem. 2016 Jul 19;11(14):1517-30. doi: 10.1002/cmdc.201600148. Epub 2016 Jun 16.

Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).

Author information

1
Global Development, Global Program Management, Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, 07981, USA. william.scott@bayer.com.
2
Former Bayer Research Center, West Haven, CT, 16516, USA.
3
Global Drug Discovery, Project Management Drug Discovery, Bayer Pharma AG, 13353, Berlin, Germany.
4
Global Drug Discovery, TRG Oncology, Bayer Pharma AG, 13353, Berlin, Germany.
5
Global Drug Discovery, Structural Biology, Bayer Pharma AG, 13353, Berlin, Germany.
6
Global Drug Discovery, Medicinal Chemistry Berlin, Bayer Pharma AG, 13353, Berlin, Germany.
7
Global Drug Discovery, Medicinal Chemistry Berlin, Bayer Pharma AG, 13353, Berlin, Germany. julien.lefranc@bayer.com.

Abstract

The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in many disease states, including tumor cells, either by growth factor receptor tyrosine kinases or by the genetic mutation and amplification of key pathway components. A variety of PI3K isoforms play differential roles in cancers. As such, the development of PI3K inhibitors from novel compound classes should lead to differential pharmacological and pharmacokinetic profiles and allow exploration in various indications, combinations, and dosing regimens. A screening effort aimed at the identification of PI3Kγ inhibitors for the treatment of inflammatory diseases led to the discovery of the novel 2,3-dihydroimidazo[1,2-c]quinazoline class of PI3K inhibitors. A subsequent lead optimization program targeting cancer therapy focused on inhibition of PI3Kα and PI3Kβ. Herein, initial structure-activity relationship findings for this class and the optimization that led to the identification of copanlisib (BAY 80-6946) as a clinical candidate for the treatment of solid and hematological tumors are described.

KEYWORDS:

PI3K inhibitors; X-ray crystallography; copanlisib; lipid kinases; phosphoinositide 3-kinase

PMID:
27310202
PMCID:
PMC5094563
DOI:
10.1002/cmdc.201600148
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center